Novel sarsasapogenin-triazolyl hybrids as potential anti-Alzheimer's agents: Design, synthesis and biological evaluation
- 1 May 2018
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 151, 351-362
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of China (81373925)
- Project of Innovation Team (LT2015027)
- Scientific Research Program of Hainan Province (ZDYF2016143)
This publication has 41 references indexed in Scilit:
- Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?EPMA Journal, 2013
- Bioinorganic Chemistry of Alzheimer’s DiseaseChemical Reviews, 2012
- Neurotoxicity of Amyloid -Protein: Synaptic and Network DysfunctionCold Spring Harbor Perspectives in Medicine, 2012
- Resveratrol and health – A comprehensive review of human clinical trialsMolecular Nutrition & Food Research, 2011
- Role of CREB in the regulatory action of sarsasapogenin on muscarinic M1receptor density during cell agingFEBS Letters, 2010
- Drug hybridization strategies: before or after lead identification?Expert Opinion on Drug Discovery, 2009
- A Century of Alzheimer's DiseaseScience, 2006
- Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in VivoJournal of Biological Chemistry, 2005
- Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseasesNature Cell Biology, 2004
- Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)Neuron, 1994